Alnuctamab (Alnuc; Bms-986349; Cc-93269), A Bcma x Cd3 T-Cell Engager, In Patients (Pts) With Relapsed/Refractory Multiple Myeloma (Rrmm): Latest Results From A Phase 1 First-In-Human Clinical Study
Alnuctamab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Alnuctamab (Alnuc; Bms-986349; Cc-93269), A Bcma x Cd3 T-Cell Engager, In Patients (Pts) With Relapsed/Refractory Multiple Myeloma (Rrmm): Latest Results From A Phase 1 First-In-Human Clinical Study ### Output: Alnuctamab